Alexis Kayser

By Alexis Kayser

Healthcare Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


This is a preview of the October 2 edition of Access Health—Tap here to get this newsletter delivered straight to your inbox.


October is off to a spooky start here in the United States. Federal funding ran dry on Wednesday at midnight after senators failed to pass the Republican-sponsored spending bill. They mostly voted along party lines, with three Democrats voting in favor of the bill and only one Republican voting against it. But ultimately, the 55-45 vote fell short of the 60 "yeses" needed to prevent a government shutdown.

Read More on Health Care

The dialogue on Capitol Hill thrust health care into the limelight. The majority share of Democrats refused to sign the GOP's funding extension unless it compromised on certain health care issues, like the continuation of Affordable Care Act subsidies that are set to expire at the year's end. (More on that in the next section.) The majority share of Republicans refused to ink a Dem-sponsored counter bill that would extend those ACA tax credits and reverse Medicaid cuts made earlier this year. Both parties are blaming each other for the shutdown, with Republicans falsely claiming that Democrats insisted on funding health care for illegal immigrants. (Here is Newsweek's fact check on that allegation.)

But the blame game is pretty low on health care leaders' priority list this week. It's unclear how long the deadlock will last, and vital health care services and policies are hanging in the balance:

Just to name a few.

Among the most concerning consequences is the failure to extend Medicare telehealth flexibilities, which officially expired yesterday. One quarter of Medicare beneficiaries utilized a telehealth service in 2024, according to CMS.

CMS has issued guidance asking people to hold off on claims submissions for 10 days. In a newsletter on Wednesday morning, the agency said clinicians "may choose to hold claims associated with telehealth services that are not payable by Medicare in the absence of Congressional action," and confirmed that "Medicare would not be able to pay some kinds of practitioners for telehealth services."

"It's a body blow," Kyle Zebley, head of public policy at the American Telemedicine Association, told me on Wednesday morning. "It is the biggest setback for our community since the beginning of the pandemic, the beginning of the decade."

Telehealth flexibilities have broad, bipartisan support, according to Zebley. No leaders have gone on the record in opposition to them, and Trump himself has been "the most transformative president" when it comes to telehealth permissions, he said.

In an ideal world, this shutdown would be short-lived, the flexibilities would be reactivated, and CMS would retroactively reimburse delayed claims, Zebley continued. But he doesn't suggest that hospital leaders cross their fingers.

Each Medicare provider "has to think through what their risk tolerance is," he said. "It's not one size fits all."

Some providers may be able to continue providing telehealth services and eat their potential losses without devastating consequences. Others may want to "wait out the storm," Zebley said, and submit claims after CMS' recommended 10-day break.

But some won't be able to offer these services without guaranteed reimbursement. That, Zebley said, is "deeply disappointing."

"Their government has unfortunately failed them," he said.

Read on to the Executive Edge section for Zebley's advice on communicating uncertainty to your workforce. And for more information on Medicare telehealth flexibilities, visit CMS' website.

U.S. Capitol

...


In Other News

Major health care headlines from the week


Pulse Check

Executive perspectives on key industry issues

Shev Partovi

...

Last week, I promised you more insights from Dr. Shez Partovi, chief innovation and strategy officer and chief business leader of enterprise informatics at Philips. He had a long career in health care and tech before landing at Philips; his resume includes a decade as a practicing neuroradiologist, served as chief digital officer for Dignity Health and heading the global health care life sciences business at AWS.

Partovi and I recently sat down to discuss Philips' AI strategy, what's working for their customers and the global challenges that they're up against. Find a portion of our conversation below:

Editor's Note: Responses have been lightly edited for length and clarity.

Shez, you said that Philips' AI solutions fall into two buckets: automation, which aims to pass off operational and administrative duties to AI, and augmentation, which aims to make clinicians more effective caregivers.

Augmentation technology requires more of a workflow change and is still at a lower adoption rate than automation technology. What are leaders at the most successful health systems doing to support clinicians and get them on board with augmentative AI?

We, as an industry, have gone through the digital transformation like 10, 15 years ago, and so this is similar to that journey. And the most common requirement in order to take physicians through a change journey of this digital transformation of 15 years ago, or the AI transformation of today, is demonstrating impact and outcomes on patient care, quality time spent.

For example, physicians want to know that with this technology, they have more face time with patients. Patients want to know the same thing. Physicians want to know that this technology is going to improve outcomes, reduce morbidity, reduce death and complications. And so our job as a technology provider is to do the clinical studies that demonstrate the impact and the positives: it delivers better care and to more people. We need to do that and publish it.

And the change leaders in the organizations lead with that impact and say there's evidence that shows this tool finds more lung lesions or reduces time and complication in [specific medical procedures]. It's our responsibility to demonstrate impact, and I find the most effective transformation journeys in health systems is when they lead with that impact on better patient care and better outcomes. Less pajama time, they call it. Less doctors working evenings, less cognitive load, lower cost. So it really is evidence driven. It isn't cool tech, anecdotally, "look, it's so neat!" Health systems that lead with impact get better adoption.

What are the biggest headwinds that companies like Philips are up against as you create and deploy these AI tools?

I will give you some of the highlights. It's no surprise that we're really going through regionalization, globally. There's deglobalization happening, and so regions have developed [differently]. Let's look at AI together for a moment. The AI Act in Europe is vastly different than the way FDA is looking at AI, vastly different than Japan and APAC or Latin America or even China. We want to do all this automation/augmentation, but now, of course, there's a lot of data sovereignty, which is appropriate, so data should stay with the bounds of the country.

So for us, from a challenge point of view, I have isolated environments in China, isolated environments in Europe, isolated appropriately following regulatory terms. I'm not calling it a bad thing. I'm just saying we have to accommodate these regionalization forces that says, "My data should stay here." Got it. We'll do that. "AI should be built in my country and use my country." Got it. Will do. That means that we have to have teams that are aware of these right-to requirements and the way in which we go through it.

And then, of course, to be sensitive to the fact that the AI needs to be able to support the patient population which it's trained on. So that's one example where the regionalization in the world has a consequence on what I would call the pace of innovation diffusion. Now that [William Gibson] quote that says, "The future is already here, it's just not evenly distributed," is what we are facing. I see the pace of AI innovation and distribution differently based on some of these regions.

And as a global company, we have to accommodate a product that might be available in North America. Then we have to see whatever requirements [are required for compliance in] this [other] market.

I use AI as an example, but it equally applies to local manufacturing. The countries increasingly say, "Look, X percent of your manufacturing needs to be local." So if I'm going to make a product, and China wants over 70 percent of that manufacturing locally—then [in another country], they also want regionalization of manufacturing and supply chain.

Of course, the one thing we learned from COVID-19 is how to be resilient. And of course, we've done a lot of that. These are some headwinds, as you put it, that we all face. It's not unique to Philips. These are global headwinds and we, like every other company, navigate them, build resilience and embrace them.

But I think the net effect, if you think of it from a patient's point of view, means that there is a difference in diffusion of innovation across the world because of this.

Are there certain countries whose regulations lend themselves to a quicker pace of innovation, while others are on the slower side? Which regions are pulling ahead and which are falling behind?

We're still so early that some of these generative AI and agentic models aren't even approved by any country, so we are in the lead time to even see how they these approvals [will go].

But what we do see are these differences. For example, the FDA has decided that the way they would do AI approvals is in the process of the medical device review of the FDA, which is terrific. We have expertise. We know how the FDA process goes, and so we're doing this in line with that. But because we know the FDA process review, we have talent and scale [there]. We work in the FDA, so the AI review is in the same stream, great.

Meanwhile, Europe has decided they will have an AI act separate from the EU Medical Device Regulation (MDR). So now you have a scenario where in the European Union, you have both a medical device rating or pathway, and a separate AI approval pathway. Now this is still the early phases. It's not the indicator they're going to go through with it in every way, but you can see how that may impact the pace of approvals in Europe, where you have to go through two mechanisms, as opposed to inline.

Our CEO [at Philips] expressed publicly that we think that may have a slowing effect. It's not that we're saying there should be no regulation, but that if you fraction it in that way, we worry that it will have a slowing effect, at least.

Then you have countries in some regions of the Middle East, the leader of that country wakes up and says, you know, this is good for our citizens, and we'll just decide to have it opened up and deployed. And so we think that some of those regions of the world where it really is top-down decision may actually foster a slipstream way in which AI innovation can reach patients.

They're all playing out right now. So none of them have landed, I mean, there's not a single agentic AI that I know that anyone has gone through a rate for review and approval. In a year from now, when you and I speak, we'll see if this actually impacts the pace that [AI models are] coming out the door, but from the early signals and the differences in the way countries are approaching AI regulation, we believe it will. And we think there should be caution in that, while there is a need for regulation, there is a need for patient safety review, that these vast differences may slow the diffusion of AI innovation.


C-Suite Shuffles

Where health care leaders are coming and going


Executive Edge

Advice for health, wellness and leadership from other health care leaders

Kyle Zebley

...

Yesterday, I asked Kyle Zebley, head of public policy at the American Telemedicine Association, how he recommends that health care leaders handle uncertainty in the health care system and communicate with their workforce during periods of unknown, such as the one we're entering with the government shutdown and telehealth regulations in limbo. Here's what he told me:

Editor's Note: Responses have been lightly edited for length and clarity.


This is a preview of the October 10 edition of Access Health—Tap here to get this newsletter delivered straight to your inbox.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines